{
    "nct_id": "NCT05896163",
    "official_title": "A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION",
    "inclusion_criteria": "* Histologically confirmed diagnosis of DLBCL\n* Relapsed or refractory disease\n* Participant is not be a candidate for or is unwilling to undergo high dose chemotherapy and subsequent stem cell transplant and/or is unable to receive chimeric antigen receptor (CAR) T-cell therapy\n* Previous treatment with at least two prior lines of systemic therapy (for phase 2, at least 2 and no more than 4 prior lines of systemic therapy). Prior therapy must include an anti-CD20 antibody.\n* Adequate bone marrow, hepatic and renal function\n* Eastern Cooperative Oncology Group (ECOG) â‰¤2\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with anti-CD47 and/or prior glofitamab or anti-CD20 x CD3 containing regimen. Refractoriness to an obinutuzumab monotherapy containing regimen.\n* Prior allogeneic stem cell transplantation or autologous stem cell transplantation within 12 weeks prior to enrolment\n* High Grade B-Cell Lymphoma\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection.",
    "miscellaneous_criteria": "Key"
}